Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Immunotherapy. M. D. Anderson Cancer Center, Houston, Texas, United States

Survival: 13.4 months
Toxicity Grade: 4
Treatments: Biologic therapy
Drugs: Thalomid
Country: United States
City/State/Province: Houston, Texas
Hospital: M. D. Anderson Cancer Center
Journal: Link
Date: 6/2006

Patients: This Pilot trial involved 15 patients with metastatic renal cell carcinoma. There were 13 men and 2 women and the median age was 59. Thirteen patients had undergone prior nephrectomy.

Treatment: The treatment consisted of a type of immunotherapy (interferon) and biological therapy (Zoledronate a drug that is a member of the bisphosphonate group, and Thalidomide a drug that is thought to be anti-angiogenic).

Toxicity: Two patients discontinued treatment because of adverse drug reactions (1 deep venous thrombosis and 1 myocardial infarction). Grade 4 toxicities included cardiac ischemia, dyspnea, and anemia.

Results: The median overall survival was 13.4 months (58 weeks).

Support: The study was supported in part by a grant from Novartis which also provided the Zoledronate free of charge.

Correspondence: Shi-Ming Tu, MD

E-mail to a Friend Email Physician More Information